Skip to content
drillr.ai

UTHR

United Therapeutics Corporation

NASDAQ · USHealthcareBiotechnology
$529.34-1.18%

Price as of Jul 20, 2026

UTHR news

United Therapeutics Corporation news

A server-rendered, paginated timeline of the latest available company news.

  1. United Therapeutics Corporation Acquires Thymmune Therapeutics

    United Therapeutics Corporation Acquires Thymmune Therapeutics United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the im

    Business Wire ·

  2. United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion

    United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion LungFX™ is the first device approved for centralized ex vivo lung perfusion for donor organs not otherwise used for transplant, an important step in advancing United Therapeutics’ platforms United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LungF

    Business Wire ·

  3. United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

    United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026 The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF) preserved lung function as measured by absolute forced vital capacity (FVC) and demonstrated reduced risk of a clinical worsening event, meeting both its primary endpoint and a key secondary endpoint with statistical significance

    Business Wire ·

  4. United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

    United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) Ralinepag achieved statistical significance for important secondary endpoints, reducing levels of N-terminal pro-B-type natriuretic peptide

    Business Wire ·

  5. Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease

    Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease PR Newswire EL SEGUNDO, Calif., May 13, 2026 The research collaboration will be the first ever to focus on space-based drug formulation that could result in therapies for patients. EL SEGUNDO, Calif., May 13, 2026 /PRNewswire/ -- Varda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgra

    PR Newswire ·

  6. United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

    United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026 Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) include efficacy and safety results from TETON-1 and integrated results from TETON-1 and TETON-2 Results from the successful ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension

    Business Wire ·

  7. United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

    United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026 An interim analysis of the PHINDER study identifies non-invasive measures that may facilitate earlier detection and management of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD) An interim analysis from the ARTISAN study indicates that early, high-dose treatment with treprostinil reduced afterload, improved right v

    Business Wire ·

  8. United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

    United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine The pivotal study of Tyvaso® (treprostinil) Inhalation Solution demonstrated a statistically significant preservation of lung function across all subgroups, as measured by absolute forced vital capacity (FVC), and fewer clinical worsening events, compared with placebo over 52 weeks in patients with idiopathic pulmonary fibrosis (IPF) Study authors noted TETON-

    Business Wire ·